MSN Pharmaceuticals Inc.

MSN Pharmaceuticals Inc. is the U.S. subsidiary of MSN Laboratories Private Limited (India), the entity behind the Hyderabad-based MSN Group. It is a Delaware corporation with a principal place of business at 20 Duke Road, Piscataway, New Jersey, and is wholly owned by MSN Laboratories. MSN Group was founded in 2003 and remains privately held; the company states it employs over 15,000 people, and third-party business databases estimate annual revenue in the roughly $500M–$1B range. MSN Pharmaceuticals itself does not appear to publish separate financials.

Operations. MSN Laboratories describes itself as a research-based pharmaceutical manufacturer with 17 API and 8 finished-dosage facilities across India, the U.S., Indonesia and the UAE, more than 500 active pharmaceutical ingredients and 400+ formulations spanning roughly 35 therapeutic areas, plus an in-house R&D center covering both API and formulation work. Its U.S. arm markets, imports and sells generic pharmaceutical products, including through Abbreviated New Drug Applications (ANDAs) filed with the FDA. The group also does contract research and manufacturing (CRAMS/CDMO) work and branded generics, notably in India and emerging markets.

Litigation posture. MSN Pharmaceuticals is an operating company, not an NPE. In our tracked data it has one appearance, as a defendant, and none as a plaintiff — consistent with a generic manufacturer defending Hatch-Waxman/ANDA patent suits brought by brand-name drug owners. The sole tracked case sits in the District of New Jersey, where MSN's U.S. office is located and where much ANDA litigation against generic filers is filed.

Notable case. Celgene Corp. v. MSN Laboratories Private Limited et al., No. 2:22-cv-01993 (D.N.J., filed April 6, 2022), was a patent-infringement action over MSN's ANDA No. 210245 for a pomalidomide product (brand: Pomalyst), asserting U.S. Patents 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467; and 10,555,939. The parties entered a consent judgment on June 15, 2022, enjoining MSN from infringing those patents until their expiration. Public dockets show MSN entities as repeat ANDA defendants in other jurisdictions, though only this case appears in our tracked list.